Chugai Pharmaceutical Co Ltd
TSE:4519
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4 684
7 855
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Chugai Pharmaceutical Co Ltd
Cash from Operating Activities
Chugai Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash from Operating Activities
ÂĄ409.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
27%
|
||
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash from Operating Activities
ÂĄ876.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
||
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash from Operating Activities
ÂĄ583.9B
|
CAGR 3-Years
73%
|
CAGR 5-Years
25%
|
CAGR 10-Years
17%
|
||
Otsuka Holdings Co Ltd
TSE:4578
|
Cash from Operating Activities
ÂĄ379.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
||
S
|
Shionogi & Co Ltd
TSE:4507
|
Cash from Operating Activities
ÂĄ187.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
3%
|
CAGR 10-Years
12%
|
|
Astellas Pharma Inc
TSE:4503
|
Cash from Operating Activities
ÂĄ200.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
Chugai Pharmaceutical Co Ltd
Glance View
Chugai Pharmaceutical Co., Ltd., a pivotal player in the pharmaceutical industry, finds its roots deeply intertwined with innovations in biotechnology. Established in Tokyo, Chugai has carved out a niche by focusing on the development and distribution of prescription pharmaceuticals tailored to address some of the most challenging medical conditions. The company's collaboration with Roche, a global healthcare leader, has strategically positioned it within the Roche Group, allowing access to an expansive trove of research and development resources. This partnership amplifies Chugai's innovative efforts, particularly in biologics and oncology, where they develop antibodies and therapies that have been instrumental in advancing clinical treatments worldwide. The synergy of Chugai's science-driven approach, coupled with Roche's global reach, has fostered a dynamic research environment that continues to push the boundaries of medical treatment possibilities. Revenue streams for Chugai are primarily anchored in the research, development, and subsequent commercialization of novel pharmaceuticals. The company gains its financial strength through successful product launches, sustained sales of flagship products, and collaborative research agreements. Chugai's extensive pipeline, particularly in the fields of oncology, immunology, and renal diseases, reflects a strategic emphasis on addressing unmet medical needs, with a considerable portion of their earnings reinvested into further research. Additionally, strategically negotiated licensing agreements allow Chugai to bolster its financial health by sharing its innovations with other industry players, maximizing distribution channels while ensuring a steady cash influx. Through this intricate balance of innovation, strategic partnerships, and a robust commercial network, Chugai not only thrives within the competitive pharmaceutical landscape but also contributes significantly to the global healthcare ecosystem.
See Also
What is Chugai Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
409.9B
JPY
Based on the financial report for Sep 30, 2024, Chugai Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 409.9B JPY.
What is Chugai Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
27%
Over the last year, the Cash from Operating Activities growth was 58%. The average annual Cash from Operating Activities growth rates for Chugai Pharmaceutical Co Ltd have been 17% over the past three years , 21% over the past five years , and 27% over the past ten years .